Risperdal Gynecomastia Trial Awards $1.75M For Breast Growth and Mental Anguish
Written by Stephen Fields on November 10, 2015
According to Bloomberg, the latest Risperdal gynecomastia lawsuit trial has awarded $1.75M to the plaintiff, including damages for disfigurement and mental anguish. The plaintiff, Tim Stange, alleged he experienced unnatural breast growth as a result of taking Risperdal. His neurologist, the doctor who prescribed the drug, claims he would not have done so had he been made aware of the gynecomastia risk.
Stange’s lawsuit is one of more than 1,500 that are pending against Johnson & Johnson and Janssen Pharmaceuticals in a growing mass tort in Philadelphia. Like Stange, other male plaintiffs allege their use of Risperdal caused them to develop female-like breasts.
The current trial is the third one of 2015 citing a connection between Risperdal and breast growth in adolescent boys. The first ended with $2.5 million in damages awarded to the plaintiff. The second ended in a mixed verdict; the plaintiff received no damages, but the jury found that J&J failed to sufficiently warn about the risk of gynecomastia. This latest case was watched closely by plaintiffs and their attorneys to discern how jurors responded to testimony and evidence.
You may be able to file a Risperdal claim for compensation if you or your son experienced abnormal breast development after taking J&J’s antipsychotic. Please call 1-888-210-9968 to discuss your case with a seasoned drug injury lawyer. Find out if you’re eligible to join the pending litigation and pursue a Risperdal gynecomastia settlement.
Plaintiff’s Doctor Claims “I’d Have Chosen A Different Medication”
Dr. Edward Kovnar, a pediatric neurologist, prescribed Risperdal to Stange in 2006 to help manage symptoms stemming from the latter’s Tourette syndrome. He prescribed the drug until 2009.
While testifying, Kovar stated he was not aware the neuroleptic posed any greater risk of male breast growth than other atypical antipsychotics. He seemed to regret the decision to prescribe the drug to Stange. Kovar remarked “If I had the same deck of cards to play with, I’d make the same decision. But if I had a full deck of cards, and all the information, I’d have chosen a different medication.”
The defendant’s attorney pointed out that the safety label for Risperdal has noted the risk of gynecomastia since 2007. In response, Kovar asked where he could find the label. He asked the attorney whether the label appeared on the bottle, was delivered by a Janssen salesperson or if he was required to submit a formal request to receive it.
He noted “If I had known where to look for it, I would have looked for it.”
When Did J&J Learn Of The Risperdal And Gynecomastia Link?
The tendency for Risperdal to cause breast growth in adolescent boys may possibly be traced to elevated prolactin levels resulting from therapy. Using the drug often causes serum prolactin levels to rise, a condition called hyperprolactinemia.
Prolactin itself is not a harmful substance. It’s a naturally-occurring protein that plays an important role in breast enlargement and lactation in expecting and new mothers. The problem is that elevated levels can bring about the same effects in adolescent boys.
Scientific research has shown since at least 1999 that Risperdal may cause an increase in prolactin levels. The Journal of Clinical Psychopharmacology published a study that year demonstrating the effect. The Journal of Anatomy published a study 10 years earlier showing that raised serum prolactin can trigger breast enlargement.
Drug manufacturers are expected to stay current on research concerning their medications. It’s reasonable to assume J&J knew about the above effect and how it might impact young boys taking its neuroleptic.
Johnson & Johnson has been manufacturing and marketing Risperdal since 1994. That was the year it was approved by the U.S. Food and Drug Administration. At the time, it was only approved to treat select mental disorders in adults. In 2006, the FDA broadened the range of approved indications, clearing Risperdal for the treatment of irritability in children with autism.
According to the defense attorney in the latest Risperdal breast growth lawsuit in 2015 to go to trial, the safety label was updated in 2007. But evidence shows J&J should have been aware of the risk years beforehand.
On Filing A Risperdal Breast Growth Lawsuit
If you or your soon took Risperdal and later experienced unnatural breast development, you’re not alone. Thousands of other young men are suffering through the same ordeal. More importantly, you may be due to receive compensation for having to endure the disorder. Call us toll-free at 1-888-210-9968 for a free case evaluation.
A pharmaceutical drug liability attorney will review the facts surrounding your case and determine your eligibility to file a Risperdal gynecomastia claim. If you decide to do so, there are never any legal fees unless we win your case and obtain a financial recovery for you.
There is limited time to file a Risperdal breast growth claim. Contact our offices at your earliest convenience to find out when the statute of limitations expires in your state. Our attorneys will provide answers to your questions about pursuing a Risperdal injury settlement, along with the latest status updates on the growing litigation.